Knee osteoarthritis or degenerative arthritis of the knee is the inflammation of the knee joints. It is a wear and tear, degenerative type of arthritis that is generally affects individuals above the age of 50 years; however, it can also occur in younger individuals. The cartilage in the knee joint gradual wears away in knee osteoarthritis. The knee joint becomes frayed and rough as the protective space in-between the bones reduces as the cartilage wears off. This causes friction in between the bones, which leads to painful bone spurs. The most common cause of this condition include age, rising weight, inherited abnormalities, repetitive stress injuries, heavy & stressful activities, and other illnesses such as rheumatoid arthritis and metabolic disorders. Symptoms of this conditions include swelling, warmth sensation in the joint, knee stiffness, and decrease in mobility. 

The prominent factor contributing to the growth of the knee osteoarthritis is the rising prevalence of the condition among the general population observed across the globe. According to the Global Burden of Disease Study, in 2010, knee osteoarthritis accounted for 80% of the total osteoarthritis burden. Osteoarthritis is a common joint disease and a major cause of disability and chronic pain in the U.S and other developed countries. According to the data provided by the U.S. Centers for Disease Control and Prevention (CDC) in 2015, an estimated 15 million people reported of severe joint pain. with knee joint pain being the most prominent condition. The number of cases are expected to increase further in the next few years. This, in turn, is expected to drive the demand for therapies and medications used in the treatment of this condition. 

Surge in geriatric population is expected to drive the knee osteoarthritis treatment market during the forecast period. Severity and incidence of knee joint pain caused due osteoarthritis increases with age. According to United Nations’ World Population Ageing report, the number of people above the age of 60 years stood at 962 million in 2017, which is projected to reach 2.1 billion by 2050. Rise in geriatric population is anticipated to increase the number of individuals suffering from knee osteoarthritis, which is expected to drive the demand for medications & therapies used to manage these conditions. 

Pharmaceutical companies launching new products launches to provide improved treatment options to people suffering from knee osteoarthritis. In March 2018, Bioventus, a leading global provider of orthobiologic solutions launched DUROLANE, a hyaluronic acid (HA) single-injection product deployed for joint lubrication. It is used in the management of pain caused due to knee osteoarthritis in the U.S. DUROLANE joins the company existing knee osteoarthritis products GELSYN-3, a three-injection HA product launched in 2016 and SUPARTZ FX, a five-injection HA launched in 2015. In May 2016, Anika Therapeutics, Inc., an integrated orthopedics medicines company launched CINGAL, the company’s 3rd generation viscosupplement in Canada to treat pain caused due to knee osteoarthritis. The launch of new and effective treatment options for managing this condition is likely to boost the knee osteoarthritis treatment market during the forecast period from 2018 to 2026. 

The global knee osteoarthritis treatment market can be segmented based on treatment type, end-user, and region. In terms of treatment type, the knee osteoarthritis treatment market can be classified into non-surgical treatment and surgical treatment. The non-surgical treatment segment is divided into drugs, alternate therapies, and others. Based on end-user, the knee osteoarthritis treatment market can be divided into hospitals, ambulatory surgical centers, and specialty clinics. 

In terms of region, the global knee osteoarthritis treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market due to the launch of new treatment options in the region. The market in Asia Pacific is projected to expand during the forecast owing to the increase in geriatric population in the region. 

Key players operating in the global knee osteoarthritis treatment market include Bioventus, AVM Biotechnology, Anika Therapeutics, Inc, Flexion Therapeutics, and OrthoTrophix, Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.       

.